Oxford Cannabinoid Technologies Holdings plc is a United Kingdom-based pharmaceutical company developing prescription cannabinoid medicines. The Company is working with three types of cannabinoid compounds: synthesized phytocannabinoids, cannabinoid derivatives and novel chemical entities. Its drug development pipeline comprises both natural and synthetic compounds, and includes compounds targeting trigeminal neuralgia, a severe type of face pain, and cannabinoid derivatives targeting pain and other therapeutic areas.
It has a portfolio of four drug development programs: Program 1 (OCT461201), Program 2 (OCT130401), Program 3 (Cannabinoid derivative) and Program 4 (Cannabinoid derivative). Its OCT461201 is a new chemical entity, CB2 receptor agonist, chemically synthesized to behave like a cannabinoid. Its OCT130401 is a drug/device combination.
It has a portfolio of over 500 derivatives and intellectual property rights, including 14 patent families and associated research data..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 19.0M |
| Three Month Average Volume | 273.3M |
| High Low | |
| Fifty-Two Week High | 0.01375 GBX |
| Fifty-Two Week Low | 0.0005 GBX |
| Fifty-Two Week High Date | 10 Aug 2023 |
| Fifty-Two Week Low Date | 08 May 2024 |
| Price and Volume | |
| Current Price | 0.00115 GBX |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -25.12% |
| Thirteen Week Relative Price Change | -75.06% |
| Twenty-Six Week Relative Price Change | -86.05% |
| Fifty-Two Week Relative Price Change | -89.62% |
| Year-to-Date Relative Price Change | -82.71% |
| Price Change | |
| One Day Price Change | -4.17% |
| Thirteen Week Price Change | -73.26% |
| Twenty-Six Week Price Change | -84.67% |
| Five Day Price Change | -43.90% |
| Fifty-Two Week Price Change | -88.78% |
| Year-to-Date Price Change | -81.60% |
| Month-to-Date Price Change | -14.81% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.00407 GBX |
| Book Value Per Share (Most Recent Quarter) | 0.00203 GBX |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.00407 GBX |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.00203 GBX |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.00509 GBX |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 GBX |
| Revenue Per Share (Trailing Twelve Months) | 0 GBX |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 GBX |
| Dividend Per Share (Trailing Twelve Months) | 0 GBX |
| Dividend Per Share (5 Year) | -99999.99 GBX |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.00619 GBX |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.00441 GBX |
| Normalized (Last Fiscal Year) | -0.00619 GBX |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.00619 GBX |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.00441 GBX |
| Including Extraordinary Items (Last Fiscal Year) | -0.00619 GBX |
| Including Extraordinary Items (Trailing Twelve Months) | -0.00441 GBX |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.00239 GBX |
| Cash Per Share (Most Recent Quarter) | 0.00118 GBX |
| Cash Flow Per Share (Last Fiscal Year) | -0.00615 GBX |
| Cash Flow Per Share (Trailing Twelve Months) | -99999.99 GBX |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.00396 GBX |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 46.11% |
| EPS Change (Trailing Twelve Months) | 33.68% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 0 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -1,134,000 |
| Net Debt (Last Fiscal Year) | -2,297,340 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 8 |
| Current Ratio (Most Recent Quarter) | 3 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -6,868,250 |
| Free Cash Flow (Trailing Twelve Months) | -3,798,480 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -72.88% |
| Return on Assets (Trailing Twelve Months) | -82.98% |
| Return on Assets (5 Year) | -56.41% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -86.76% |
| Return on Equity (Trailing Twelve Months) | -104.70% |
| Return on Equity (5 Year) | -66.36% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -86.76% |
| Return on Investment (Trailing Twelve Months) | -104.70% |
| Return on Investment (5 Year) | -66.13% |